Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Glaxosmithkline plc save search
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
Published: 2023-11-28 (Crawled : 21:00) - biospace.com/
UNCY | $0.49 -2.47% 5.0% 100K
|
Professional, Scientific, and T...
|
| O: -2.05%
H: 0.0%
C: 0.0%
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: -0.51%
H: 0.96%
C: 0.54%
GERN | $1.99 3.11% 0.5% 4.1M
|
Health Technology
|
| O: -1.05%
H: 2.65%
C: 1.06%
corporation
Gonorrhea Therapeutics Market to grow by USD 506.68 million from 2022 to 2027; North America accounts for 39% of market growth - Technavio
Published: 2023-11-21 (Crawled : 20:00) - prnewswire.com
GLAXF | $18.25 5.74% -0.49% 3.8K
|
Health Technology
|
| O: -3.23%
H: 0.0%
C: -0.35%
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: -0.23%
H: 0.2%
C: -0.28%
america therapeutics growth market
Ewing's Sarcoma Treatment Market to grow by USD 205.09 million from 2024-2028; North America to account for 48% of market growth - Technavio
Published: 2023-11-20 (Crawled : 19:00) - prnewswire.com
NVS | $98.13 0.24% -0.16% 1.2M
|
Health Technology
|
| O: 0.91%
H: 0.6%
C: 0.27%
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: 0.51%
H: 0.77%
C: 0.26%
BAX | $36.55 1.3% -0.08% 4.2M
|
Health Technology
|
| O: 0.39%
H: 0.2%
C: -0.17%
america treatment growth market
Unraveling the Shifting Rare Eye Diseases Market Landscape: Analysis of Retinoblastoma Market, Retinitis Pigmentosa Market, Limbal Stem Cell Deficiency Market, Leber Hereditary Optic Neuropathy Market, and Stargardt Disease Market | DelveInsight
Published: 2023-11-16 (Crawled : 22:00) - prnewswire.com
NVS | $98.13 0.24% -0.16% 1.2M
|
Health Technology
|
| O: 1.19%
H: 0.0%
C: 0.0%
JNJ | $158.38 2.41% 0.0% 10M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
ABT | $104.88 0.57% -0.01% 4.7M
|
Health Technology
|
| O: 2.58%
H: 0.0%
C: 0.0%
SNY | $46.72 -0.06% 0.06% 1.2M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
rare disease cell eye market
Digital Dose Inhaler Market Set for Remarkable Growth, Estimated at $104.3 Billion by 2033
Published: 2023-11-16 (Crawled : 01:00) - prnewswire.com
GLAXF | $18.25 5.74% -0.49% 3.8K
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
AZNCF | $125.0 -2.72% 8.8% 3.4K
|
Health Technology
|
| O: -2.16%
H: 4.44%
C: 2.2%
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
MMM | $99.85 0.79% 0.04% 2.8M
|
Producer Manufacturing
|
| O: 0.25%
H: 0.0%
C: 0.0%
AZN | $64.79 0.31% 0.03% 3.6M
|
Health Technology
|
| O: -0.22%
H: 0.71%
C: 0.6%
set market
CureVac veröffentlicht Finanzergebnisse für das dritte Quartal sowie die ersten neun Monate 2023 und informiert über seine Geschäftsentwicklung
Published: 2023-11-14 (Crawled : 12:00) - curevac.com
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
CVAC | $5.5 1.85% 3.64% 380K
|
Health Technology
|
| O: 8.15%
H: 0.0%
C: 0.0%
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-13 (Crawled : 22:00) - globenewswire.com
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
SCYX | $1.72 2.38% -0.58% 510K
|
Health Technology
|
| O: 3.79%
H: 0.0%
C: 0.0%
update financial results
Adult Vitamin Gummies Market to grow by USD 2.75 billion from 2023-2028; North America to account for 41% of market growth - Technavio
Published: 2023-11-10 (Crawled : 23:00) - prnewswire.com
UNLYF | $47.86 -0.4% 5.94% 2K
|
Consumer Non-Durables
| Email alert
Add to watchlist
UL | $47.91 0.44% -0.46% 2.5M
|
Consumer Non-Durables
| Email alert
Add to watchlist
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | $18.25 5.74% -0.49% 3.8K
|
Health Technology
| Email alert
Add to watchlist
america growth market
23andMe Reports Second Quarter Fiscal 2024 Financial Results
Published: 2023-11-08 (Crawled : 21:00) - globenewswire.com
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
| Email alert
Add to watchlist
financial results
Global mRNA Vaccine Market Research Report 2023-2028: COVID-19 Success Opens New Avenues with with 444 Ongoing Clinical Studies Worldwide
Published: 2023-11-08 (Crawled : 03:00) - prnewswire.com
GLAXF | $18.25 5.74% -0.49% 3.8K
|
Health Technology
|
| O: 1.91%
H: 0.0%
C: 0.0%
VERV 2 d | $11.79 4.52% 0.09% 1.4M
|
Professional, Scientific, and T...
|
| O: 14.28%
H: 0.64%
C: -10.76%
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: 0.47%
H: 0.46%
C: -0.23%
MRNA | $79.83 2.74% 0.06% 4M
|
Health Technology
|
| O: 1.55%
H: 0.0%
C: 0.0%
CVAC | $5.5 1.85% 3.64% 380K
|
Health Technology
|
| O: 1.09%
H: 1.08%
C: -1.44%
BNTX | $99.4 -1.01% -1.29% 800K
|
Health Technology
|
| O: 4.26%
H: 0.08%
C: -2.81%
ARCT | $24.87 3.89% -0.52% 300K
|
Health Technology
|
| O: 4.66%
H: 0.79%
C: -0.61%
covid-19 success report vaccine mrna worldwide ongoing research global market
COVID-19 Challenges Drive the Need for Resilient Supply Chains and Digital Healthcare in the Anti-Epileptic Drugs Market, Shaping the Post-Pandemic Landscape
Published: 2023-11-06 (Crawled : 19:00) - prnewswire.com
VTRS | $9.37 2.07% 0.0% 7.4M
|
Health Technology
|
| O: -0.54%
H: 0.33%
C: -0.98%
TEVA | $9.71 -1.12% 0.0% 6.6M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
TAK | $14.17 0.14% 0.0% 830K
|
Health Technology
|
| O: 0.44%
H: 0.22%
C: 0.07%
NVS | $98.13 0.24% -0.16% 1.2M
|
Health Technology
|
| O: 0.38%
H: 0.18%
C: 0.16%
JNJ | $158.38 2.41% 0.0% 10M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
ABT | $104.88 0.57% -0.01% 4.7M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
SNY | $46.72 -0.06% 0.06% 1.2M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
covid-19
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
Published: 2023-11-06 (Crawled : 14:30) - biospace.com/
ENDPQ | $0.0025 300.0% 120K
|
n/a
|
| O: 0.0%
H: 0.0%
C: -25.71%
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: 1.43%
H: 0.82%
C: 0.38%
NRBO | $0.4499 0.42% 0.0% 31K
|
Health Technology
|
| O: 2.1%
H: 0.0%
C: 0.0%
pharmaceuticals
CureVac meldet Fortschritte in klinischen Phase-2-Entwicklungsprogrammen für COVID-19 und die saisonale Grippe in Zusammenarbeit mit GSK
Published: 2023-11-01 (Crawled : 13:00) - curevac.com
GLAXF | $18.25 5.74% -0.49% 3.8K
|
Health Technology
|
| O: -1.62%
H: 0.0%
C: 0.0%
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: -3.0%
H: 0.0%
C: 0.0%
CVAC | $5.5 1.85% 3.64% 380K
|
Health Technology
|
| O: 1.92%
H: 3.95%
C: -1.32%
covid-19
Medical Segment Dominates, Expected to Reach $70.4 Billion by 2030 in the Global Recombinant DNA Technology Market
Published: 2023-11-01 (Crawled : 01:00) - prnewswire.com
GLAXF | $18.25 5.74% -0.49% 3.8K
|
Health Technology
|
| O: -1.62%
H: 0.0%
C: 0.0%
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
|
| O: 1.94%
H: 2.55%
C: 2.55%
NVO | $100.4 -1.41% 0.3% 4.6M
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
NVS | $98.13 0.24% -0.16% 1.2M
|
Health Technology
|
| O: 0.19%
H: 0.7%
C: 0.57%
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: -3.0%
H: 0.0%
C: 0.0%
LLY 2 d | $584.04 -1.18% 0.34% 3.6M
|
Health Technology
|
| O: -2.76%
H: 0.0%
C: 0.0%
SNY | $46.72 -0.06% 0.06% 1.2M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
expected reach global dna medical technology market
Premature Ejaculation (PE) Treatment Market size to grow by USD 1.45 billion from 2023-2028| A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd., and more among the key companies in the market - Technavio
Published: 2023-10-31 (Crawled : 22:00) - prnewswire.com
GLAXF | $18.25 5.74% -0.49% 3.8K
|
Health Technology
|
| O: -1.62%
H: 0.0%
C: 0.0%
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: -3.0%
H: 0.0%
C: 0.0%
VERU | $1.01 5.75% -0.99% 560K
|
Health Technology
|
| O: -1.68%
H: 2.25%
C: -6.4%
companies treatment pharmaceuticals market
CureVac veröffentlicht am 14. November 2023 Finanzergebnisse des dritten Quartals sowie der ersten neun Monate 2023 und informiert über seine Geschäftsentwicklung
Published: 2023-10-31 (Crawled : 15:30) - curevac.com
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
CVAC | $5.5 1.85% 3.64% 380K
|
Health Technology
|
| O: 1.56%
H: 0.0%
C: 0.0%
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
Published: 2023-10-30 (Crawled : 12:00) - globenewswire.com
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: 0.03%
H: 0.44%
C: -0.23%
collaboration extension agreement
Anti-inflammatory Therapeutics Market Size to Hit US$ 149.5 billion by 2031 | Exclusive Study by Transparency Market Research
Published: 2023-10-30 (Crawled : 09:00) - prnewswire.com
SNYNF | $94.0 1.34% 1.34% 860
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: 0.0%
PFE | $28.91 -5.12% 0.0% 100M
|
Health Technology
|
| O: -2.42%
H: 0.0%
C: 0.0%
NVS | $98.13 0.24% -0.16% 1.2M
|
Health Technology
|
| O: -0.15%
H: 0.25%
C: -0.07%
JNJ | $158.38 2.41% 0.0% 10M
|
Health Technology
|
| O: -1.39%
H: 0.79%
C: 0.64%
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: 0.03%
H: 0.44%
C: -0.23%
ABBV | $143.41 0.72% -0.11% 4.9M
|
Health Technology
|
| O: 2.87%
H: 0.0%
C: 0.0%
SNY | $46.72 -0.06% 0.06% 1.2M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
research therapeutics study market
Non-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51% of market growth- Technavio
Published: 2023-10-27 (Crawled : 19:00) - prnewswire.com
AZN | $64.79 0.31% 0.03% 3.6M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $125.0 -2.72% 8.8% 3.4K
|
Health Technology
| Email alert
Add to watchlist
GLAXF | $18.25 5.74% -0.49% 3.8K
|
Health Technology
| Email alert
Add to watchlist
IVEVF | $3.73 0% 1K
|
n/a
| Email alert
Add to watchlist
IVA | $4.32 2.86% 3.01% 4.1K
|
Health Technology
| Email alert
Add to watchlist
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
| Email alert
Add to watchlist
america market
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
Published: 2023-10-27 (Crawled : 11:00) - globenewswire.com
GSK | $36.57 1.61% -0.06% 2.5M
|
Health Technology
|
| O: -2.19%
H: 0.0%
C: 0.0%
ALEC | $5.56 2.58% -0.54% 480K
|
Health Technology
|
| O: 0.76%
H: 0.38%
C: -3.57%
dementia trial
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
ID 4 | $0.077 -9.41% 25.97% 420K
|
Finance
BKKT 4 | $1.88 25.33% 14.89% 4.8M
|
MGLD | $1.03 7.77% 14K
|
Manufacturing
CZOO | $0.4316 -6.52% 6.7% 65K
|
AUMN | $0.562 0.34% 4.5% 360K
|
Non-Energy Minerals
SAIC 4 | $119.92 2.14% 4.24% 460K
|
Technology Services
CULP 4 | $5.06 -0.59% 3.95% 29K
|
Process Industries
LGL 4 | $4.94 1.23% 3.04% 15K
|
Electronic Technology
TELL | $0.65 6.73% 2.99% 41M
|
Energy Minerals
CVNA 4 | $35.2 12.39% 2.84% 12M
|
Retail Trade
Your saved searches
Save your searches and get alerts when important news are released.